Health Care

ProText Mobility’s botanical drug innovation faces steep financial hurdles: a declining stock, negative P/E, and OTC listing challenge its future growth prospects.

Medical Marijuana, Inc. pioneers global CBD research, offering therapeutic oils and tinctures while driving innovation in healthcare.

Dexcom’s CGM tech proves reliable in a Swiss insulin‑patch pilot, delivering accurate real‑time glucose data with no failures – a key step for integrated diabetes care.

Chemed Corporation secures a $450 million revolving credit line, boosting liquidity, flexibility for acquisitions and growth in healthcare and restoration services.

Share‑holding changes at German health‑care firm Eckert & Ziegler SE boost European distribution, improve liquidity and set the stage for stronger governance and growth.

SoftOx Solutions AS secures private placement to fund its biofilm‑eradication drugs, boosting capital for next‑stage trials and infection‑treatment breakthroughs.

Almirall SA’s stock volatility and high P/E signal a risky investment, even as the Spanish pharma firm’s dermatology focus may limit growth amid fierce competition.

Revenio Group Oyj’s €250 m Visionix acquisition aims to become a turnkey eye‑care leader, doubling its TAM, boosting EBITDA and expanding OCT expertise by Q2 2026.

Centessa Pharmaceuticals’ acquisition by Eli Lilly shows how big pharma is turning to data‑driven biotech to refresh pipelines, boost sleep‑disorder treatments and navigate patent expirations amid regulatory uncertainties.

Explore iX Biopharma’s journey from pioneering pain‑management wafers like Wafermine to nutraceuticals, amid market volatility and a challenging P/E ratio.